Dr. Lorch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
676 N St Clair St
Chicago, IL 60611Phone+1 312-695-6180Fax+1 312-695-6189
Education & Training
University of RegensburgClass of 1994
Certifications & Licensure
IL State Medical License 1999 - 2026
MA State Medical License 2005 - 2022
ME State Medical License 2020 - 2021
PA State Medical License 1997 - 1999
Clinical Trials
- A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Jul 22
Roles: Principal Investigator
Publications & Presentations
PubMed
- 1 citationsDual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial.Kartik Sehgal, Theodora Pappa, Kee-Young Shin, Julia Schiantarelli, Mofei Liu
JAMA Oncology. 2024-12-01 - 3 citationsPrecision medicine in aggressive thyroid cancer: Moving beyond multitargeted tyrosine kinase inhibitors.Umair Mahmood, Jochen H. Lorch
Cancer Cytopathology. 2021-11-08 - 58 citationsNeoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck.Glenn J. Hanna, Anne O'Neill, Kee-Young Shin, Kristine S. Wong, Vickie Y. Jo
Clinical Cancer Research. 2021-10-19
Press Mentions
Immunotherapy Shows Potential to Treat Deadly Thyroid CancerNovember 20th, 2024- Immunotherapy Shows Potential to Treat Deadly Thyroid CancerNovember 19th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
